ALEXANDERS., BRENDLERH.: Treatment of uric acid urolithiasis with allopurinol: a xanthine oxidase inhibitor. J. Urol. (Baltimore), 97: 340–344: 1967.
2.
ANDERSONE. E., RUNDLESR. W., SILBERMANH. R., METZE. N.: Allopurinol control of hyperuricemie: a new concept in the prevention of uric acid stones. J. Urol. (Baltimore), 97: 344–47: 1967.
3.
ATSMONA., DE VRIESA., FRANKM.: Uric acid lithiasis.Elsevier, Amsterdam, London, New York, 1963, pag. 178.
4.
BIBUSB.: Beitrag zur Zitronentherapie der Uratsteine. Urol. int., 14: 28–41: 1962.
5.
BUSCHERH. K.: Therapie der Nieren und Harnleitersteine. in Handbuch der Urologie, Vol. X, Springer Verlag, Berlin, Göttingen, Heidelberg1961.
6.
HALLA. P., HOLLOWAYV. P., SCOTTJ. T.: 4-Hydroxypyrazolo (3,4-d) pyrimidine (HPP) in the treatment of gout. Preliminary observations. Ann. Reum. Dis., 23: 439–446: 1964.
7.
HAYESC. P. jr., METZE. N., ROBINSONR. R., RUNDLESR. W.: The use of allopurinol (HPP) to control hyperuricemia in patients on chronic intermittent hemodialysis. Trans. Amer. Soc. Artif. Int. Organs, 11: 247–54: 1965.
8.
KLINENBERGJ. R., GOLDFINGERS. E., SEEGMILLERJ. E.: The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout. Ann. Int. Med., 62: 639–47: 1965.
9.
PASEROA., RICCIONIN., RIZZOG.: Prime esperienze con un inibitore della xantinossidasi (allopurinolo) nel trattamento di soggetti gottosi con grave compromissione della funzione renale. Settimana med., 54: 1049–57: 1966.
10.
PAVONEM.: Calcolosi renale, in SorrentinoM.: Trattato Italiano di Urologia, vol. II, E.S.I., Napoli1958.
11.
RUNDLESR. W., METZE. N., SILBERMANH. R.: Allopurinol in the treatment of gout. Ann. Int. Med., 64: 229–58: 1966.
12.
RUNDLESR. W., SILBERMANH. R., HITCHINGSG. H., ELIONG. B.: Effects of xanthine oxidase inhibitor on clinical manifestations and purine metabolism in gout. Ann. Int. Med., 60: 717–18: 1964.
13.
RUNDLESR. W., WYNGAARDENJ. B., HITCHINGSG. H., ELIONG. B., SILBERMANH. R.: Effects of a xanthine oxidase inhibitor of thiopurine metabolism, hyperuricemia and gout. Trans. Ass. Amer. Phys., 76: 126–140: 1963.
14.
SORRENTINOF.: II tungsteno nella prevenzione della calcolosi da acido urico. Atti Soc. it. Urol., XXX Congresso, Napoli 1957.
15.
SORRENTINOF.: Experimentelle Untersuchungen über Möglichkeiten einer biologischen Behandlung der Harnsäuresteine. Zschr. Urol., 52: 281–29: 1959.
16.
SORRENTINOF.: Molibdeno, tungsteno e vanadio e metabolismo dell'acido urico. Arch. Sci. Med., 110: 383–87: 1960.
17.
WYNGAARDENJ. B.: Gout, in LevineR., & LuftR. Editors, Advances in Metabolic Disorders, Academic Press, New York & London, Vol. 2°, 1965.
18.
WYNGAARDENJ. B., RUNDLESR. W., METZE. N.: Allopurinol in the treatment of gout. Ann. Int. Med., 62: 842–47: 1965.
19.
WYNGAARDENJ. B., RUNDLESR. W., SILBERMANH. R., HUNTERSS.: Control of hyperuricemia with hydroxypyrazolopyrimidine, a purine analogue which inhibits uric acid synthesis. Arthr. Reumat., 6: 306–07: 1963.
20.
YUT. F., GUTMANA. B.: Effect of allopurinol (4-hydroxypyrazolo 3,4-d pyrimidine) on serum and urinary uric acid in primary and secondary gout. Amer. J. Med., 37: 885–898: 1964.
